Epithelial ovarian cancer is a malignant tumor that arises from the epithelial cells lining the ovary. It is the most common type of ovarian malignancy, accounting for 85% to 90% of cases, primarily affecting women aged 40 and older. There is a significant clinical need for advanced therapies, as current treatment options have limitations. The growing focus on immunotherapy and targeted therapies will drive the advancements in epithelial ovarian cancer therapeutics. With ongoing research and innovation, the market for epithelial ovarian cancer treatment is expected to witness significant growth, improving treatment outcomes in the coming years.
Major companies involved in the epithelial ovarian cancer pipeline drugs market include Hoffmann-La Roche, Amino Up Co., Ltd., and others.
Leading drugs currently in the pipeline include Bevacizumab, SHR-A1921, RC88, and others.
The growing demand for targeted therapies, advancements in immunotherapy, and intensified research on resistance mechanisms are supporting the expansion of the epithelial ovarian cancer drug pipeline.
The Epithelial Ovarian Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into epithelial ovarian cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for epithelial ovarian cancer. The epithelial ovarian cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The epithelial ovarian cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with epithelial ovarian cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to epithelial ovarian cancer.
Epithelial ovarian cancer is the most common type of ovarian cancer, originating in the epithelial cells lining the ovaries. It occurs due to genetic mutations that lead to uncontrolled cell growth, often linked to factors such as aging, family history, and hormonal influences. The disease typically remains asymptomatic in early stages, making early detection challenging.
Epithelial ovarian cancer is treated through a combination of surgery and chemotherapy. Surgery involves tumor removal, often including the ovaries, fallopian tubes, and uterus. Chemotherapy, using platinum-based drugs like carboplatin and paclitaxel, targets residual cancer cells. Individual treatment plans are based on cancer stage, genetic factors, and patient health conditions.
Epithelial ovarian cancer accounts for 85%-90% of ovarian malignancies, primarily affecting women over 40 years. In 2022, the United States reported over 19,000 new cases and 12,000 deaths. The United Kingdom records around 7,400 cases annually, with incidence expected to rise by 15% by 2035. In India, it ranks third among female cancers, with 47,333 cases and 32,978 deaths in 2022.
This section of the report covers the analysis of epithelial ovarian cancer drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total epithelial ovarian cancer clinical trials.
The drug molecule categories covered under the epithelial ovarian cancer pipeline analysis include monoclonal antibodies, small molecules, gene therapies, peptides, and cell therapies. The epithelial ovarian cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for epithelial ovarian cancer.
The EMR report for the epithelial ovarian cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed epithelial ovarian cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in epithelial ovarian cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for epithelial ovarian cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of epithelial ovarian cancer drug candidates.
Avastin (bevacizumab) is currently undergoing a Phase IV clinical development, in which it is being evaluated in patients with advanced/metastatic epithelial ovarian, fallopian tube, or primary peritoneal cancer. The study, sponsored by Hoffmann-La Roche, aims to assess the drug’s safety and efficacy in real-world clinical settings. Bevacizumab, an anti-angiogenic monoclonal antibody, inhibits VEGF, reducing tumor blood supply and growth.
SHR-A1921 is an investigational therapy sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. in a Phase III trial. This study evaluates its efficacy and safety in platinum-resistant recurrent epithelial ovarian cancer, comparing it to standard chemotherapy options—doxorubicin, paclitaxel, and topotecan. With an estimated enrollment of 440 patients, the results could advance future treatment approaches.
RC88 is an antibody-drug conjugate (ADC) targeting mesothelin (MSLN). RemeGen Co., Ltd. is sponsoring this Phase II trial to evaluate RC88 for platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The study aims to assess the drug’s efficacy, safety, and pharmacokinetics.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Epithelial Ovarian Cancer Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for epithelial ovarian cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into epithelial ovarian cancer collaborations, regulatory environments, and potential growth opportunities.
Global Ovarian Cancer Diagnostics and Therapeutics Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share